Alzheimer’s Treatment Shows Promise in Small, 3-Year Trial
TUESDAY, July 17 (HealthDay News) — An immune-based drug therapy using blood plasma antibodies has stalled the progression of Alzheimer’s disease in a small group of patients receiving the therapy over three years.